Analysis of efficacy, safety and economic comparison of first h. Pylori eradication treatment with a potassium ion-competitive acid blocker and proton pump inhibitors
- In: Poster presentation
- At: Seoul (South Korea) (2017)
- Type: Poster
- Poster code: POS-HPS-129
- By: TSUCHIDA, Junnosuke (Kameda Medical Center, Kamogawa, Japan)
- Co-author(s): Junnosuke Tsuchida:
Masahito Nakazaki: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
Kosuke Hashizawa: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
Ryokan Funakoshi: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
Vonoprazan Fumarate (VPZ), is a novel P-CAB (potassium competitive acid blocker) first introduced in Japan in February 2015. At that time, our hospital’s recommended regimen for the eradication of H. pylori did not include VPZ.
In order to revise the recommended regimen, we compared the efficacy and safety of proton pump.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019